Literature DB >> 18443124

Pharmacokinetics and tissue distribution of anidulafungin in rats.

Bharat Damle1, Martin Stogniew, James Dowell.   

Abstract

This study assessed the tissue distribution of anidulafungin in rats. Anidulafungin rapidly distributed into tissues, achieving peak concentrations within 30 min, and maintained levels above MICs for common pathogens over 72 h. In tissues susceptible to fungal infection (liver, lung, spleen, kidney), exposure was 9- to 12-fold higher than in plasma.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18443124      PMCID： PMC2443878          DOI： 10.1128/AAC.01596-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Autoradiography using storage phosphor technology.

Authors:  R F Johnston; S C Pickett; D L Barker
Journal:  Electrophoresis       Date:  1990-05       Impact factor: 3.535

2.  Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.

Authors:  Tawanda Gumbo; George L Drusano; Weiguo Liu; Robert W Kulawy; Christine Fregeau; Vasha Hsu; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2006-12-28       Impact factor: 5.191

Review 3.  Anidulafungin: a novel echinocandin.

Authors:  Jose A Vazquez; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2006-06-09       Impact factor: 9.079

4.  Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.

Authors:  Tawanda Gumbo; George L Drusano; Weiguo Liu; Lei Ma; Mark R Deziel; Michael F Drusano; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2006-09-05       Impact factor: 5.191

5.  In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species.

Authors:  G G Zhanel; J A Karlowsky; G A Harding; T V Balko; S A Zelenitsky; M Friesen; A Kabani; M Turik; D J Hoban
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

6.  Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats.

Authors:  Toshiro Niwa; Yoshiko Yokota; Akira Tokunaga; Yasuhiro Yamato; Akira Kagayama; Tomoichi Fujiwara; Junko Hatakeyama; Masaharu Anezaki; Yuko Ohtsuka; Akira Takagi
Journal:  Biol Pharm Bull       Date:  2004-07       Impact factor: 2.233

7.  A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis.

Authors:  David S Krause; A E Simjee; Christo van Rensburg; Johann Viljoen; Thomas J Walsh; Beth P Goldstein; Michele Wible; Timothy Henkel
Journal:  Clin Infect Dis       Date:  2004-08-27       Impact factor: 9.079

8.  Anidulafungin versus fluconazole for invasive candidiasis.

Authors:  Annette C Reboli; Coleman Rotstein; Peter G Pappas; Stanley W Chapman; Daniel H Kett; Deepali Kumar; Robert Betts; Michele Wible; Beth P Goldstein; Jennifer Schranz; David S Krause; Thomas J Walsh
Journal:  N Engl J Med       Date:  2007-06-14       Impact factor: 91.245

9.  Disposition of caspofungin, a novel antifungal agent, in mice, rats, rabbits, and monkeys.

Authors:  Punam Sandhu; Xin Xu; Peter J Bondiskey; Suresh K Balani; Michael L Morris; Yui S Tang; Alisha R Miller; Paul G Pearson
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

10.  Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.

Authors:  Julie A Stone; Xin Xu; Gregory A Winchell; Paul J Deutsch; Paul G Pearson; Elizabeth M Migoya; Goutam C Mistry; Liwen Xi; Alisha Miller; Punam Sandhu; Romi Singh; Florencia deLuna; Stacy C Dilzer; Kenneth C Lasseter
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191
View more
  26 in total

Review 1.  Pharmacokinetics of antifungal agents in children.

Authors:  Kevin Watt; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Early Hum Dev       Date:  2011-02-01       Impact factor: 2.079

Review 2.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

3.  SCY-078, a Novel Fungicidal Agent, Demonstrates Distribution to Tissues Associated with Fungal Infections during Mass Balance Studies with Intravenous and Oral [14C]SCY-078 in Albino and Pigmented Rats.

Authors:  Stephen Wring; Katyna Borroto-Esoda; Eric Solon; David Angulo
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

Review 4.  Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.

Authors:  Effie L Kuti; Joseph L Kuti
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-10       Impact factor: 4.481

5.  Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.

Authors:  Jared L Crandon; Mary Anne Banevicius; Annie F Fang; Penelope H Crownover; R Fredrick Knauft; J Samuel Pope; John H Russomanno; Eric Shore; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2009-09-21       Impact factor: 5.191

6.  CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility.

Authors:  B Radha Krishnan; Kenneth D James; Karen Polowy; B J Bryant; Anu Vaidya; Steve Smith; Christopher P Laudeman
Journal:  J Antibiot (Tokyo)       Date:  2016-08-10       Impact factor: 2.649

7.  Activities of systemically administered echinocandins against in vivo mature Candida albicans biofilms developed in a rat subcutaneous model.

Authors:  Sona Kucharíková; Nidhi Sharma; Isabel Spriet; Johan Maertens; Patrick Van Dijck; Katrien Lagrou
Journal:  Antimicrob Agents Chemother       Date:  2013-02-12       Impact factor: 5.191

Review 8.  Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients.

Authors:  Kevin J Downes; Brian T Fisher; Nicole R Zane
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

9.  In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin.

Authors:  Bharat D Damle; James A Dowell; Robert L Walsky; Gregory L Weber; Martin Stogniew; Philip B Inskeep
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

Review 10.  Tissue penetration of antifungal agents.

Authors:  Timothy Felton; Peter F Troke; William W Hope
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.